11+ hour, 9+ min ago   (260+ words) Six patients who had lived with binge eating disorder for as long as two decades sat down for two infusions of an experimental psychedelic drug. Three months later, all of them were still doing better. Half of them had not…...

5+ day, 7+ hour ago   (444+ words) The United States National Institutes of Health has agreed to fund a multimillion-dollar program that will give up to 200 Americans living with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology company Neurizon Therapeutics. The grant,…...

2+ week, 6+ day ago   (624+ words) Genetic Signatures has emerged from a year of restructuring with smaller losses, lower cash burn, and a clearer plan to rebuild growth, despite a decline in revenue amid challenging conditions in its core Australian market. The molecular diagnostics company reported…...

3+ week, 6+ day ago   (311+ words) Dimerix has taken over sponsorship of a United States investigational new drug application for DMX-652, giving the Australian biotechnology company direct control of clinical development plans for its newly acquired acute kidney injury asset. The Melbourne-based company said the transfer from…...